Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. METHODS AND FINDINGS: NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid. CONCLUSIONS: The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease. TRIAL REGISTRATION: Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A phase III trial (NCT02017340) testing the efficacy and safety of nilvadipine (29) in participants with mild to moderate AD indicated that, while the drug demonstrated good safety, it did not show significant benefits in slowing cognitive decline in AD patients.477”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [477]
The cited source says what the claim attributes to it.
In the citing paper
“The dihydropyridine calcium channel blocker nilvadipine with a capacity of lowering Aβ production and increasing clearance Aβ was evaluated for neuroprotective and anti-inflammatory properties (Lawlor et al., 2018).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Lawlor et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 1×
“In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease [12,13].”
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,374
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 1×
“In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease [12,13].”
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
“Three 5HT6 antagonists and the calcium channel blocker nilvadipine 203,204 have also been ineffective.”
Self-citationRetractedAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
Metadata
- Authors
- Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., Breuilh, L., Daly, L., Hendrix, S., Aisen, P., Gaynor, S., Sheikhi, A., Taekema, D. G., Verhey, F. R., Nemni, R., Nobili, F., Franceschi, M., Frisoni, G., Zanetti, O., Konsta, A., Anastasios, O., Nenopoulou, S., Tsolaki-Tagaraki, F., Pakaski, M., Dereeper, O., de la Sayette, V., Sénéchal, O., Lavenu, I., Devendeville, A., Calais, G., Crawford, F., Mullan, M., & for the NILVAD Study Group
- Affiliations
- Trinity College Dublin (IE)
- University College Dublin (IE)
- King's College London (GB)
- Université de Lille (FR)
- G. Papanikolaou General Hospital (GR)
- Mario Negri Institute for Pharmacological Research (IT)
- University College Cork (IE)
- St. James's Hospital (IE)
- Universität Ulm (DE)
- University of Szeged (HU)
- University of Limerick (IE)
- University of Southern California (US)
- Rijnstate Hospital (NL)
- Maastricht University (NL)
- University of Milan (IT)
- Ospedale Policlinico San Martino (IT)
- MultiMedica (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Aristotle University of Thessaloniki (GR)
- Centre Hospitalier d'Arras (FR)
- Centre Hospitalier de Lens (FR)
- Centre Hospitalier de Béthune (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Groupe Hospitalier de l'Institut Catholique de Lille (FR)
- Roskamp Institute (US)
- Corresponding author
- Lawlor, Brian
- ORCID
- Lawlor, Brian
- Segurado, Ricardo
- Olde Rikkert, Marcel G. M.
- Howard, Robert
- Pasquier, Florence
- Tsolaki, Magda
- Lucca, Ugo
- Molloy, D. William
- Riepe, Matthias W.
- Kálmán, János
- Kenny, Rose Anne
- Walsh, Cathal
- Banzi, Rita
- Daly, Leslie
- Hendrix, Suzanne
- Aisen, Paul
- Sheikhi, Ali
- Verhey, Frans R.
- Nobili, Flavio
- Franceschi, Massimo
- Frisoni, Giovanni
- Zanetti, Orazio
- Konsta, Anastasia
- Nenopoulou, Styliani
- Tsolaki-Tagaraki, Fani
- Lavenu, Isabelle
- Crawford, Fiona
- Mullan, Michael
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-09-24
- Volume
- 15
- Issue
- 9
- Pages
- e1002660
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6152871
- OpenAlex
- W2891955176
- Cited by
- 193
- References
- 29
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 36 · 2020: 49 · 2019: 24 · 2018: 1
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Cork Open Research Archive (University College Cork, Ireland) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc-sa)
- Figshare (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Limerick Institutional Repository (University of Limerick) (submittedVersion, cc-by-nc-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (NF-SI-0616-10042)
- European Commission (279093)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- University College London Hospitals NHS Foundation Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- nilvadipine, Alzheimer's disease, cognitive decline, dihydropyridine calcium channel blockers, disease-modifying therapy, Clinical Dementia Rating, NINCDS-ADRDA criteria, anti-inflammatory activity, amyloid, regional cerebral blood flow, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Male, Middle Aged, Nifedipine, Treatment Outcome, Disease Progression, Nootropic Agents, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1002660
- The paper
- Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., . . . for the NILVAD Study Group. (2018). Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002660
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.